The Global Cancer Biomarkers Market was valued at US$ 13.5 Billion in 2023 and is projected to reach US$ 24.6 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 12.7% during the forecast period (2023–2028). This growth is being driven by rising cancer incidences worldwide, advancements in genomic and proteomic technologies, and the increasing adoption of precision oncology approaches in diagnostics and therapeutics across various cancer types.

As the oncology field evolves toward personalized and targeted treatments, the emphasis is on innovative biomarker developers who are enhancing early detection, risk assessment, and therapy monitoring. In this blog, we profile the Top 10 Companies in the Cancer Biomarkers Industry—a blend of diagnostic powerhouses, biotech innovators, and pharmaceutical leaders pioneering the next era of cancer care.

---

🔟 1. BioMerieux SA

Headquarters: Marcy-l’Étoile, France
Key Offering: Protein Biomarkers, Genetic Biomarkers for infectious and oncology diagnostics

BioMerieux SA stands out as a key player in the cancer biomarkers space, leveraging its expertise in molecular diagnostics to deliver solutions that identify biomarkers for early cancer detection and monitoring. The company’s portfolio includes advanced assays that support clinical decisions in oncology, particularly for cancers like colorectal and breast, through platforms like the VIDAS system which detects protein-based biomarkers with high sensitivity.

BioMerieux’s focus on integrating biomarkers into routine clinical workflows has positioned it as a trusted partner for healthcare providers globally. By combining automated systems with biomarker research, they enable faster and more accurate diagnoses, ultimately improving patient outcomes in resource-limited settings as well.

Research and Development Initiatives:

• Ongoing collaborations with academic institutions to validate novel protein biomarkers for lung cancer

• Expansion of genetic biomarker panels for personalized therapy selection in solid tumors

• Commitment to regulatory approvals for companion diagnostics in emerging markets

Download FREE Sample Report: 2023-2028 Global and Regional Cancer Biomarkers Industry Status and Prospects Professional Market – View in Detailed Research Report

---

9️⃣ 2. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Genetic Biomarkers, Protein Biomarkers for targeted therapies

Novartis AG plays a pivotal role in the cancer biomarkers industry by integrating biomarker discovery into its robust pharmaceutical pipeline. Their work emphasizes genetic biomarkers that guide the use of targeted drugs, such as those for breast and lung cancers, through platforms that analyze mutations like BRCA or EGFR to tailor treatments effectively.

The company’s approach combines in-house R&D with strategic partnerships to accelerate biomarker validation, ensuring that their diagnostics align seamlessly with therapeutic advancements. This integration has led to breakthroughs in companion diagnostics that not only detect cancer but also predict response to specific therapies, reducing trial-and-error in patient care.

Research and Development Initiatives:

• Investments in AI-driven biomarker discovery for immunotherapy response prediction

• Global clinical trials focusing on biomarker-driven trials for rare cancers

---

8️⃣ 3. Hologic, Inc.

Headquarters: Marlborough, Massachusetts, USA
Key Offering: Genetic Biomarkers for women’s health and oncology

Hologic, Inc. excels in developing cancer biomarkers with a strong emphasis on gynecological cancers, including ovarian and cervical types. Their Aptima assays utilize genetic biomarkers to detect high-risk HPV strains and other molecular indicators, providing crucial data for screening and early intervention programs worldwide.

By prioritizing accessible and scalable diagnostic tools, Hologic addresses the needs of diverse populations, particularly in regions with high cervical cancer burdens. Their innovations extend to liquid biopsy technologies that monitor biomarker levels non-invasively, offering a less burdensome alternative to traditional biopsies for ongoing cancer management.

Research and Development Initiatives:

• Development of multiplex assays combining genetic and protein biomarkers for breast cancer risk assessment

• Partnerships with health organizations to implement biomarker screening in low-resource areas

---

7️⃣ 4. Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: Protein Biomarkers, Genetic Biomarkers for immuno-oncology

Merck & Co., Inc. is a leader in leveraging cancer biomarkers to advance immunotherapy, particularly through PD-L1 expression testing via protein biomarkers. Their Keytruda companion diagnostics help identify patients likely to benefit from checkpoint inhibitors in cancers such as melanoma and lung cancer, streamlining treatment selection.

The company’s commitment to biomarker research extends to large-scale genomic profiling projects, which uncover new targets and resistance mechanisms. This forward-thinking strategy not only supports current therapies but also lays the groundwork for next-generation diagnostics that could revolutionize how we approach metastatic diseases.

Research and Development Initiatives:

• Large-scale biomarker validation studies for combination therapies

• Integration of liquid biopsy biomarkers for real-time monitoring of treatment efficacy

Download FREE Sample Report: 2023-2028 Global and Regional Cancer Biomarkers Industry Status and Prospects Professional Market – View in Detailed Research Report

---

6️⃣ 5. Qiagen NV

Headquarters: Venlo, Netherlands
Key Offering: Genetic Biomarkers, Other molecular diagnostics

Qiagen NV specializes in sample-to-insight technologies that enable the detection of genetic biomarkers in cancer tissues and circulating DNA. Their QIAseq panels target actionable mutations in colorectal and prostate cancers, supporting both research and clinical applications with high-throughput sequencing solutions.

Qiagen’s strength lies in its end-to-end workflow, from sample preparation to data analysis, which minimizes errors and maximizes reproducibility in biomarker testing. This has made them indispensable in precision medicine initiatives, where reliable genetic profiling is key to identifying therapeutic vulnerabilities in tumors.

Research and Development Initiatives:

• Advancement of digital PCR for sensitive detection of low-abundance genetic biomarkers

• Collaborations with pharma companies to develop custom biomarker assays

---

5️⃣ 6. Agilent Technologies

Headquarters: Santa Clara, California, USA
Key Offering: Protein Biomarkers, Genetic Biomarkers via mass spectrometry and NGS

Agilent Technologies provides comprehensive tools for cancer biomarker discovery and validation, including mass spectrometry systems that quantify protein biomarkers in complex samples. Their solutions are widely used in proteomics research for liver and stomach cancers, aiding in the identification of novel diagnostic signatures.

The company’s integrated platforms facilitate seamless transitions from discovery to clinical validation, supporting researchers in academia and industry alike. By emphasizing reproducibility and scalability, Agilent ensures that biomarker findings translate effectively into practical diagnostic tests that benefit patients globally.

Research and Development Initiatives:

• Expansion of NGS-based genetic biomarker kits for pan-cancer analysis

• Investment in automation to enhance high-throughput protein biomarker screening

---

4️⃣ 7. Illumina, Inc.

Headquarters: San Diego, California, USA
Key Offering: Genetic Biomarkers through next-generation sequencing

Illumina, Inc. dominates the genetic biomarkers segment with its sequencing technologies that enable comprehensive genomic profiling for cancers like blood and melanoma. Their TruSight Oncology panels detect thousands of variants, helping oncologists select targeted therapies based on tumor genetics.

Illumina’s innovations in scalable sequencing have democratized access to advanced biomarker testing, allowing for broader implementation in clinical settings. Their focus on reducing costs and turnaround times has accelerated the adoption of genomic biomarkers in routine cancer care, from diagnosis to relapse monitoring.

Research and Development Initiatives:

• Current output of sequencing solutions supporting over 1 million cancer samples annually

• Target to double capacity for liquid biopsy-based genetic biomarker detection by 2026

Download FREE Sample Report: 2023-2028 Global and Regional Cancer Biomarkers Industry Status and Prospects Professional Market – View in Detailed Research Report

---

3️⃣ 8. F. Hoffmann-La Roche Ltd

Headquarters: Basel, Switzerland
Key Offering: Protein and Genetic Biomarkers for companion diagnostics

F. Hoffmann-La Roche Ltd is at the forefront of cancer biomarkers, offering integrated solutions like the cobas platform for detecting HER2 and PD-L1 biomarkers in breast and lung cancers. Their diagnostics division collaborates closely with therapeutics to ensure biomarker tests predict drug efficacy accurately.

Roche’s global reach and investment in digital pathology enhance biomarker interpretation, providing pathologists with AI-assisted tools for precise analysis. This holistic approach not only improves diagnostic accuracy but also supports epidemiological studies that inform public health strategies against cancer.

Research and Development Initiatives:

• Indigenous development of multi-omics biomarker platforms

• Public-private partnerships to scale access to genetic testing in Asia and Africa

---

2️⃣ 9. Thermo Fisher Scientific Inc.

Headquarters: Waltham, Massachusetts, USA
Key Offering: Genetic Biomarkers, Protein Biomarkers via Ion Torrent and mass spec

Thermo Fisher Scientific Inc. offers a wide array of tools for cancer biomarker research, including the Oncomine panels for NGS-based genetic analysis in prostate and ovarian cancers. Their technologies enable the detection of fusion genes and copy number variations critical for therapy guidance.

With a strong emphasis on workflow optimization, Thermo Fisher supports labs in achieving high-quality biomarker data efficiently. Their acquisitions have bolstered capabilities in proteomics, allowing for deeper insights into tumor microenvironments and potential resistance markers.

Research and Development Initiatives:

• Aims to produce advanced biomarker kits for 800 million tests annually

• Major expansion in supply chains for global distribution of diagnostic assays

---

1️⃣ 10. Abbott Laboratories

Headquarters: Chicago, Illinois, USA
Key Offering: Protein Biomarkers, Genetic Biomarkers for point-of-care diagnostics

Abbott Laboratories leads in accessible cancer biomarker testing with products like the Alinity system, which detects protein biomarkers for colorectal and blood cancers at the point of care. Their focus on rapid, user-friendly assays makes advanced diagnostics feasible in diverse healthcare environments.

Abbott’s pipeline includes innovations in circulating tumor DNA testing, providing non-invasive options for monitoring biomarker changes over time. By bridging the gap between research and clinical use, they empower physicians to make informed decisions that enhance survival rates and quality of life for cancer patients.

Research and Development Initiatives:

• End-to-end solutions for biomarker integration in global health screening programs

• Strategic alliances with research consortia to advance multi-cancer early detection

Read Full Report: 2023-2028 Global and Regional Cancer Biomarkers Industry Status and Prospects Professional Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Cancer Biomarkers Is Precise and Personalized

The cancer biomarkers market is experiencing transformative changes as technologies like next-generation sequencing and AI analytics become mainstream. While genetic and protein biomarkers currently lead in adoption, the sector is pouring resources into emerging areas such as epigenetic markers and multi-omics integration to provide a more holistic view of disease progression and treatment response.

Because of the post-COVID-19 emphasis on resilient health systems, companies are reevaluating strategies to incorporate telehealth-compatible diagnostics and expand into underserved regions. Furthermore, regulatory support for companion diagnostics is accelerating approvals, ensuring that biomarkers translate quickly from bench to bedside.

📈 Key Trends Shaping the Market:

• Increased competition driving continuous innovations in liquid biopsy and AI-enhanced interpretation

• Growing demands for new technologies like CRISPR-based biomarker detection and global regulatory alignment

• Digitalization of diagnostic workflows and real-time data sharing for collaborative oncology research

• Strategic alliances between diagnostic firms and pharma for co-development of biomarker-guided therapies

Read Full Report: 2023-2028 Global and Regional Cancer Biomarkers Industry Status and Prospects Professional Market – View in Detailed Research Report

The companies profiled here are not only advancing cancer diagnostics—they’re at the forefront of a precision medicine revolution that promises earlier interventions and more effective treatments worldwide.